Assessment of treatment response in tuberculosis. (2nd June 2016)

• Record Type: Journal Article
• Authors: Rockwood, Neesha; du Bruyn, Elsa; Morris, Thomas; Wilkinson, Robert J
• Is Part Of: Expert review of respiratory medicine. Volume 10:Number 6(2016)
• Page Start: 643
• Page End: 654
• Publication Date: 2016-06-02
• Subjects: Tuberculosis -- therapeutics -- treatment outcome -- biomarkers -- humans; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1586/17476348.2016.1166960
• Languages: English
• ISSNs: 1747-6348

Abstract

ABSTRACT: Antibiotic treatment of tuberculosis has a duration of several months. There is significant variability of the host immune response and the pharmacokinetic-pharmacodynamic properties of Mycobacterium tuberculosis sub-populations at the site of disease. A limitation of sputum-based measures of treatment response may be sub-optimal detection and monitoring of Mycobacterium tuberculosis sub-populations. Potential biomarkers and surrogate endpoints should be benchmarked against hard clinical outcomes (failure/relapse/death) and may need tailoring to specific patient populations. Here, we assess the evidence supporting currently utilized and future potential host and pathogen-based models and biomarkers for monitoring treatment response in active and latent tuberculosis. Biomarkers for monitoring treatment response in extrapulmonary, pediatric and drug resistant tuberculosis are research priorities.